Hypoxia-inducible Factor (HIF)-1α and CCN2 Form a Regulatory Circuit in Hypoxic Nucleus Pulposus Cells

CCN2 SUPPRESSES HIF-1α LEVEL AND TRANSCRIPTIONAL ACTIVITY*

Received for publication, December 26, 2012, and in revised form, March 20, 2013 Published, JBC Papers in Press, March 24, 2013, DOI 10.1074/jbc.M112.448860

Cassie M. Tran1, Nobuyuki Fujita1,2,3, Bau-Lin Huang2, Jessica R. Ong3, Karen M. Lyons3, Irving M. Shapiro1, and Makarand V. Risbud1,3

From the 1Department of Orthopaedic Surgery and Graduate Program in Cell and Developmental Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, the 2Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan 108-8345, and the 3Departments of Molecular, Cell and Developmental Biology, and Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California 90024

Background: The relationship between connective tissue growth factor (CCN2) and hypoxia-inducible factor (HIF)-1 in hypoxic nucleus pulposus is unknown.

Results: HIF-1α suppresses CCN2 expression, whereas CCN2 represses basal HIF-1α levels and transcriptional activity.

Conclusion: In nucleus pulposus, HIF-1α and CCN2 form a negative regulatory circuit.

Significance: Tight control of CCN2 and HIF-1α activities may play a role in disc homeostasis.

The objective of the study was to investigate if hypoxia-inducible factor (HIF)-1α and connective tissue growth factor (CCN2) form a regulatory network in hypoxic nucleus pulposus (NP) cells. A decrease in CCN2 expression and proximal promoter activity was observed in NP cells after hypoxic culture. Analysis of both human and mouse CCN2 promoters using the JASPAR core database revealed the presence of putative hypoxia response elements. Transfection experiments showed that both promoter activities and CCN2 expression decreases in hypoxia in a HIF-1α-dependent fashion. Interestingly, deletion analysis and mutation of the hypoxia responsive elements individually or in combination resulted in no change in promoter activity in response to hypoxia or in response to HIF-1α, suggesting an indirect mode of regulation. Notably, silencing of endogenous CCN2 increased HIF-1α levels and its target gene expression, suggesting a role for CCN2 in controlling basal HIF-1α levels. On the other hand, treatment of cells with rCCN2 resulted in a decrease in the ability of HIF-1α transactivating domain to recruit co-activators and diminished target gene expression. Last, knockdown of CCN2 in NP cells results in a significant decrease in GAG synthesis and expression of AGGRECAN and COLLAGEN II. Immunohistochemical staining of intervertebral discs of Ccn2 null embryos shows a decrease in aggrecan. These findings reveal a negative feedback loop between CCN2 and HIF-1α in NP cells and demonstrate a role for CCN2 in maintaining matrix homeostasis in this tissue.

The intervertebral disc is a unique tissue that separates adjoining vertebras and helps to accommodate biomechanical forces on the spine. Cartilagenous end plates form its superior and inferior boundaries, whereas between these end plates a ligamentous annulus fibrosus circumferentially surrounds the proteoglycan-rich nucleus pulposus. Nutrients and oxygen reach the nucleus pulposus through diffusion from blood vessels that infiltrate only the outer annulus and end plate cartilage, resulting in the characteristically hypoxic microenvironment (1–3).

Nucleus pulposus cells have adapted to survive in this hypoxic niche through robust expression of hypoxia inducible factor (HIF-1α), a transcription factor responsive to local oxygen tension (4). HIF is a basic helix-loop-helix transcription factor comprising a constitutively expressed β subunit and an α subunit that undergoes degradation by both oxygen-dependent and -independent pathways (5, 6). When stabilized, the α subunit dimerizes with the β subunit and binds to hypoxia response elements (HREs) in the promoter of target genes. In the disc, HIF-1α is critical for maintenance of nucleus pulposus cell survival, glycolytic metabolism, and functional activities including proteoglycan matrix synthesis (7–11).

Connective tissue growth factor (CCN2/CTGF) is a member of the CCN family of proteins that plays an important role in chondrogenesis and angiogenesis, where it regulates cell proliferation and migration, as well as extracellular matrix production (12–18). Signaling through integrins and other cell surface receptors, CCN proteins function to modulate growth factor activity in response to a plethora of stimuli, including oxygen tension and mechanical force (16, 17, 19–24). Mice null for Ccn2 die immediately after birth due to severe skeletal and cartilage dysplasia, indicating its importance in development (13). In a pathological context, hypoxia induces CCN2 expression in a number of cell types, including fibroblasts and lung and pancreatic adenocarcinoma, where it is associated with

The abbreviations used are: HIF-1α, hypoxia inducible factor-1α; CCN2, connective tissue growth factor; HRE, hypoxia response element; DMOG, dimethyl oxalylglycine; TAD, transactivation domain.

* This work was supported, in whole or in part, by National Institutes of Health Grants AR050087 and AR056565 (to M. R.) and AR052686 (to K. M. L.).
1 Supported by National Institute on Aging Grant F31AG038125.
2 Present address: Cancer and Developmental Biology Laboratory, National Cancer Institute, Frederick, MD.
3 To whom correspondence should be addressed: 1025 Walnut St., Suite 511 College Bldg., Thomas Jefferson University, Philadelphia, PA 19107. Tel.: 215-955-1063; Fax: 215-955-9159; E-mail: makarand.risbud@jefferson.edu.
4 The abbreviations used are: HIF-1α, hypoxia inducible factor-1α; CCN2, connective tissue growth factor; HRE, hypoxia response element; DMOG, dimethyl oxalylglycine; TAD, transactivation domain.
enhanced fibrosis and tumor growth (22, 25–28). On the other hand, in a tubular epithelial cell line, CCN2 expression is shown to decrease with hypoxia, underlying the cell type specificity of CCN2 regulation and function in response to hypoxia (30). In contrast, little information is available on the role of CCN2 in regulating HIF-1α expression (24, 31).

In the context of the disc, CCN2 has been shown to stimulate extracellular matrix production by nucleus pulposus cells (32). However, little is known about the regulation of CCN in the nucleus pulposus under normal and pathological conditions. CCN2 may play a role in the development of the notochord in zebrafish, the embryonic anlagen of the intervertebral disc (33), but a similar effect on the notochord is not seen in mice lacking CCN2 (13). We have observed increasing levels of CCN2 in the degenerate nucleus pulposus and have identified TGF-β as an important regulator of its expression. However, it is yet to be determined if CCN2 expression is controlled by hypoxia in the disc (23). Resolution of this question is important because CCN2 is a major target and regulator of hypoxic pathways in many pathological conditions. Thus, the objective of this investigation is to determine whether CCN2 expression in nucleus pulposus cells is regulated by hypoxia and HIF-1α and if CCN2, in turn, regulates HIF-1α. Results of the study show that in nucleus pulposus cells hypoxia decreases CCN2 expression through HIF-1α and that CCN2 suppresses HIF-1α activity.

**MATERIALS AND METHODS**

*Plasmids and Reagents—* Human CCN2 promoter plasmids were obtained from Dr. George Yang, Stanford University, and the mouse Ccn2 promoter plasmids were as described previously (34). Expression plasmids were provided by Dr. Celeste Simon, University of Pennsylvania (pCA-HIF-2α with a triple mutation (P405A/P530A/N851A)) and Dr. Eric Huang, National Cancer Research Institute, Bethesda (pARNT). shHIF-1α (PBS/pU6-HIF1α) (number 21103) developed by Dr. Connie Cepko, HA-HIF1α/P402A/P564A-pcDNA3 (number 18955) by William Kaelin, HRE-Luc (number 26731) by Navdeep Chandeland, and psPAX2 (number 12260) and pMD2.G (number 12259) by Didier Trono were obtained from Addgene. Lentiviral shHIF-1α that co-expresses YFP was a gift from Dr. Andree Yeremian, University of Lleida, Spain, and pre-validated pLKO.1-sh-CCN2 (TRC#0000061951) was purchased from Sigma. For transfection studies of HIF-1, the binary Gal4 reporter plasmids (N+C TAD, amino acids 530–826; N-TAD, amino acids 530–778; and C-TAD, amino acids 740–826) were provided by Dr. Nianli Sang. Backbone plasmid pM (Clontech) contains no transactivation domain (TAD) but expresses the Gal4DBD. pFR-Luc (Stratagene) reporter contains the yeast Gal4-binding site upstream of a minimal promoter and the firefly luciferase gene. pRL-TK (Promega) containing the Renilla reniformis luciferase gene was used as an internal transfection control. The amount of transfected plasmid, the pre-transfection period after seeding, and the post-transfection period before harvesting have been previously optimized for rat nucleus pulposus cells using pSVβ-galactosidase plasmid (Promega) (7).

*Isolation of Nucleus Pulposus Cells and Treatments of Cells—* Rat nucleus pulposus cells were isolated using a method reported earlier by Risbud et al. (7). Nucleus pulposus cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) and 10% fetal bovine serum (FBS) supplemented with antibiotics. Cells were cultured in a Hypoxia Work Station (Invivo2 300, Ruskinn, UK) with a mixture of 1% O2, 5% CO2, and 94% N2 for 8 to 24 h. In some experiments, cells were treated with CCN2 (100 ng/ml, Prospek, Israel), TGF-β1 (10 ng/ml, Peptrotech, NJ), or 1 mM dimethyl oxalylglycine (DMOG).

**Real Time RT-PCR Analysis—** Total RNA was extracted from nucleus pulposus cells using RNAeasy mini columns (Qiagen). Before elution from the column, RNA was treated with RNase-free DNase I (Qiagen). The purified, DNA-free RNA was converted to cDNA using Superscript III Reverse Transcriptase (Invitrogen). Template cDNA and gene-specific primers were added to the SYBR Green master mixture (Applied Biosystems) and mRNA expression was quantified using the Step One Plus Real-time PCR System (Applied Biosystems). Hprt1 and β-actin were used to normalize gene expression. Melting curves were analyzed to verify the specificity of the RT-PCR and the absence of primer dimer formation. Each sample was analyzed in duplicate and included a template-free control. All primers used were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA).

**Western Blotting—** Cells were placed on ice immediately following treatment and washed with ice-cold Hanks’ balanced salt solution. All wash buffers and final re-suspension buffer included 1× protease inhibitor mixture (Roche Applied Science), NaF (5 mM), and Na3VO4 (200 μM). Total cell proteins were resolved on 8–12% SDS-polyacrylamide gels and transferred by electroblotting to polyvinylidene difluoride membranes (Bio-Rad). The membranes were blocked with 5% non-fat dry milk in TBST (50 mM Tris, pH 7.6, 150 mM NaCl, 0.1% Tween 20) and incubated overnight at 4 °C in 3% nonfat dry milk in TBST with the anti-CCN2 (1:900, Santa Cruz), anti-CA-HIF-1α (1:1000, R&D Systems), or anti-β-tubulin antibody (1:2000, Developmental Studies Hybridoma Bank). Immunolabeling was detected using the ECL reagent (Amersham Biosciences).

**Immunofluorescence Microscopy—** Cells were plated in flat bottom 96-well plates (4 × 10^3/well) and cultured in hypoxia for 4–24 h. After incubation, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 in PBS for 10 min, blocked with phosphate buffered saline containing 5% FBS, and incubated with antibodies against CCN2 (1:200) (Abcam) at 4 °C overnight. As a negative control, cells were reacted with isotype IgG under similar conditions. After washing, the cells were incubated with Alexa Fluor-488-conjugated anti-mouse secondary antibody (Invitrogen), at a dilution of 1:50 for 45 min at room temperature. Cells were imaged using a laser scanning confocal microscope (Olympus Fluoview, Japan).

**Transfections and Dual Luciferase Assay—** Cells were transfected to 24-well plates at a density of 4 × 10^6 cells/well 1 day before transfection. To measure the effect of hypoxia, cells were transfected with 500 ng of CCN2 reporter plasmids and 500 ng of pRL-TK plasmid. To investigate the effect of HIF-1α on CCN2 promoter activity, cells were co-transfected with 100–300 ng of CA-HIF-1α, CA-HIF-2α, siHIF-1α, shHIF-2α or the respective
backbone vector along with 400 ng of CCN2 reporter and 300 ng of pRL-TK plasmid. Lipofectamine 2000 (Invitrogen) was used as the transfection reagent; for each transfection, plasmids were premixed with transfection reagent. The next day, the cells were harvested and a Dual-Luciferase® reporter assay system (Promega) was used for sequential measurements of firefly and Renilla luciferase activities. Quantification of luciferase activities and calculation of relative ratios were carried out using a luminometer (TD-20/20, Turner Designs, CA). At least three independent transfections were performed, and all analyses were carried out in triplicate.

Site-directed Mutagenesis—Site-directed mutagenesis of the human and mouse CCN2 promoters was performed according to the manufacturer’s protocol using the In-Fusion HD Cloning Kit (Clontech). Primers used for human CCN2 promoter mutants with mutated HRE sites underlined are: HRE MT1 F, 5′-AGAGAACCAAGCTGTGACTCGATGCAGTCTCCTGG-3′; HRE MT2 F, 5′-GAAGGCTAGGGCCCTTGAGGCCAGTCCACCTAAGGTGG-3′; HRE MT3 F, 5′-CAGGGAGATCTCATGTGAGGAGCCTATTTCCATTTCGTT-3′. Primers used for mouse CCN2 promoter mutants with the mutated HRE site underlined were: HRE MT1 F, 5′-TGCCCTTTGAGGTGACCAATGTA-3′; HRE MT2 F, 5′-CACACACACAAAAACAAAGAAAGAGAGAGAGAGAAGGA-3′. Mutations were verified by sequencing using the Applied Biosystems 3730 DNA Sequencer.

Lentiviral Particle Production and Viral Transduction—HEK 293T cells were seeded in 10-cm plates (1.3 × 10⁶ cells/plate) in DMEM with 10% heat-inactivated FBS 2 days before transfection. Cells were transfected with 2.5 µg of pLKO.1-Ctr, shHIF-1α, or shCCN2 plasmids along with 1.875 µg of psPAX2 and 0.625 µg of pMD2.G. After 16 h, transfection media was removed and replaced with DMEM with 5% heat-inactivated FBS and penicillin-streptomycin. Lentiviral particles were harvested at 48 and 60 h post-transfection. Nucleus pulposus cells were plated in DMEM with 5% heat-inactivated FBS 1 day before transduction. Cells in 10-cm plates were transduced with 5 ml of conditioned media containing viral particles along with 6 µg/ml of Polybrene. After 24 h, conditioned media was removed and replaced with DMEM, 5% heat-inactivated FBS. Cells were harvested for protein extraction 5 days after viral transduction.

Dimethylmethylen blue Assay—The proteoglycan content of conditioned media was measured as sulfated glycosaminoglycan by colorimetric assay with 1,9-dimethylmethylene blue (Blyscan, Biocolor Ltd., Carrickfergus, UK) with chondroitin-4-sulfate as a standard following the manufacturer’s instructions. GAGs were precipitated from conditioned media and stained with dimethylmethylen blue and staining was quantified by measuring absorbance at 656 nm. Results were calculated as GAG (µg)/total DNA (ng) and expressed relative to the value obtained for untreated controls.

Immunohistochemistry of Disc Tissue—Paraffin-embedded sections of wild type and mutant mice were boiled for 15 min in citrate buffer to reverse cross-links and unmask epitopes. Sections were blocked with 5% goat serum for 1 h and incubated with anti-CCN2 (CCN2) (Abcam, Cambridge MA) or anti-aggrecan (Millipore, Danvers, MA) at a dilution of 1:250 overnight at 4°C. The following day sections were incubated with secondary antibody (Alexa Fluor 555 or 488 goat anti-rabbit, Invitrogen) for 1 h at room temperature. Sections were counterstained with DAPI (Vectorshield, Vector Laboratories, Burlingame, CA). FAST™ staining was performed as described by Leung et al. (35).

Statistical Analysis—All measurements were performed in triplicate, data are presented as mean ± S.E. Differences between groups were analyzed by the Student’s t test; *, p < 0.05.

RESULTS

Hypoxia Decreases CCN2 Expression in Nucleus Pulposus Cells—Nucleus pulposus cells were cultured in hypoxia (1% O₂) and expression of Ccn2 was analyzed using real time RT-PCR. Fig. 1A shows that hypoxia results in a significant decrease in Ccn2 mRNA expression in nucleus pulposus cells. Western blot analysis of cellular lysates and secreted protein in conditioned media shows that Ccn2 levels are decreased by hypoxia as well (Fig. 1B). Densitometric analysis of Western blot experiments confirmed a significant decrease in both cellular and secreted CCN2 in hypoxia (Fig. 1, C and D). Immunofluorescence microscopy of cells cultured in hypoxia for 24 h confirmed that there is a decrease in CCN2 levels compared with normoxic controls (Fig. 1E).

CCN2 Promoter Contains Conserved HREs—To investigate the mechanism of transcriptional regulation of CCN2 by hypoxia, we examined the response of both human and mouse CCN2 promoters to 1% O₂. First, using the Evolutionarily Conserved Region Browser and UCSC genome browser, we observed that the first 5 kb of the CCN2 promoter is highly conserved between several vertebrate species including human, mouse, and rat (Fig. 2A). Next, we scanned the first 5 kb of the human CCN2 promoter for the presence of HREs using the JASPAR core database (36). Previous studies have experimentally validated two functional HREs within the first 5 kb of the mouse Ccn2 promoter; thus, the profile score threshold used was first optimized by analyzing the mouse promoter sequence in JASPAR as a positive control (22). At an 85% profile score threshold, the JASPAR database returned three putative HRE sites at −640/−634, −2010/−2006, and −2264/−2258 bp on the human CCN2 promoter, whose specific sequences are shown in bold in Fig. 2B. The HREs in the mouse Ccn2 promoter, however, are not conserved in location in the human promoter and vice versa, as verified by the Multiz alignment (Fig. 2B).

Hypoxia and HIF Regulation of CCN2 Promoter Activity—We then used plasmids containing either the human or mouse CCN2 promoter driving luciferase expression to measure the effect of hypoxia on promoter activity in nucleus pulposus cells (Fig. 3, A and B). Fig. 3, C and D, shows that hypoxia significantly decreases the activity of the human and mouse CCN2 promoter fragments. Serial deletion analysis of the mouse Ccn2 promoter showed that activity of smaller promoter fragments including a 0.5-kb reporter that lacked HREs is suppressed by hypoxia (Fig. 3D). To test the hypothesis that HIFs were involved in mediating the hypoxia-induced decrease in promoter activity we performed loss- and gain-of-function experi-
HIF-1 Suppresses CCN2 Promoter Activity Independent of HREs—To further examine if the HREs are necessary for promoter regulation by hypoxia, we performed site-directed mutagenesis to mutate HREs individually or in combination. Fig. 4A shows a schematic of the wild type and mutant human CCN2 promoter constructs. Cells were transfected with these constructs and luciferase activity was measured following a 24-h culture in hypoxia (Fig. 4B) or co-transfection with HIF-1α (Fig. 4C). Results show that neither individual nor any combination of HRE mutations cause a difference in response to hypoxia or HIF-1α overexpression compared with the wild type promoter (Fig. 4, B and C). We also mutated mouse Ccn2 promoter constructs (Fig. 4D) and similarly observed hypoxia suppression of the wild type and mutant reporters (Fig. 4E).

Additionally, overexpression of HIF-1α caused a decrease in promoter activity despite the mutation of one or both of the HREs, indicating HRE independent regulation of the promoter activity by HIF-1α (Fig. 4F). To delineate the possible mechanisms of this indirect regulation of CCN2 expression by hypoxia and HIF-1, we examined if hypoxia decreases the responsiveness of nucleus pulposus cells to TGF-β, an autocrine factor that maintains the CCN2 expression levels in these cells (23). Our results clearly show that hypoxia diminishes the effect of TGF-β on CCN2 expression by NP cells (Fig. 4, G and H). We then measured the activity of a wild type or CCN2 reporter containing a mutation in the Smad binding element (Fig. 4I) following co-transfection with HIF-1α. It is noteworthy that the activity of both reporters was strongly suppressed by HIF-1α (Fig. 4J).

HIF-1α Is a Negative Regulator of CCN2 Expression in Nucleus Pulposus Cells—To confirm the involvement of HIF-1α in hypoxic regulation of CCN2 expression, we performed HIF-1α loss-of-function studies. First, HIF-1α was stably knocked down in nucleus pulposus cells using lentiviral transduction of shHIF-1α. Fig. 5A shows the robust expression of YFP in lentivirus-infected cells, indicating high transduction efficiency. As expected, the mRNA expression of HIF-1α and its target gene, GAPDH, is significantly decreased following shHIF-1α expression (Fig. 5B). Correspondingly, CCN2 mRNA expression is significantly increased in HIF-1α-silenced cells (Fig. 5C). Interestingly, we found that CCN3 mRNA expression...
responded in a reciprocal manner to CCN2 (Fig. 5D). Furthermore, suppression of HIF-1α protein levels results in a significant increase in both cellular and secreted CCN2 (Fig. 6, A and B). To complement the loss-of-function experiments, we perform gain-of-function studies by treating cells with the prolyl hydroxylase inhibitor DMOG. As expected, this treatment causes an accumulation of HIF-1α; there is a simultaneous decline in CCN2 expression. Densitometric analysis of three independent experiments confirms significant induction of HIF-1α and concomitant decrease in CCN2 protein levels at 4, 8, and 24 h (Fig. 6D).

CCN2 Antagonizes HIF-1 in Nucleus Pulposus Cells—Next, we sought to determine the effect of CCN2 on the regulation of HIF-1α expression and activity. To suppress endogenous CCN2, cells were transduced with a lentiviral construct expressing shRNA against CCN2 (shCCN2-LV) or shRNA control (Ctr-LV). Real time RT-PCR analysis shows that CCN2 mRNA is decreased with shCCN2-LV transduction (Fig. 7A), whereas mRNA expression of HIF-1α and its target genes, ENOLASE 1 and VEGF, increased (Fig. 7, B–D). In contrast to HIF-1α, HIF-2α mRNA levels declined in CCN2-silenced cells (Fig. 7B). Western blot analysis was then used to follow changes at the protein level. Results show that CCN2 levels are significantly decreased in shCCN2-LV-transduced cells (Fig. 7, E and F). Moreover, in agreement to changes in mRNA expression, HIF-1α protein levels increased in CCN2-silenced cells (Fig. 7, E and F).

Next, we treated cells with recombinant CCN2 to examine if endogenous HIF-1α activity and expression is affected in a corresponding manner. Treatment with recombinant CCN2 for 24 h results in a significant decrease in HRE reporter activity (Fig. 8A). We then examined the expression of HIF-1α target genes, VEGF and ENOLASE 1, in response to CCN2 treatment and found that the expression of both genes is significantly decreased (Fig. 8B). Interestingly, Western blot and corresponding densitometric analysis showed that HIF-1α protein expression is not significantly affected by CCN2 treatment (Fig. 8, C and D). Next, we examined the mechanism by which CCN2
regulates HIF-1α activity. For this purpose, we tested if CCN2 treatment affects interactions between the transactivation domain of HIF-1α and its co-activators. Reporter constructs expressing both the N- and C-terminal TAD (Fig. 8E) were transfected into cells and their activity was measured following CCN2 treatment. Fig. 8F and G, shows that the addition of CCN2 caused a significant decrease in the activity of all HIF-1α-TAD reporters, indicating a decline in transcriptional activity. As expected the empty Gal4-DBD showed almost undetectable activity that remained unaffected by CCN2 treatment.

Finally, we measured the role of CCN2 in controlling the expression of AGGREGAN and COLLAGEN II, two important extracellular matrix genes for nucleus pulposus cells. Fig. 9A and B, confirms that the lentiviral shCCN2 efficiently surpasses the level of cellular and secreted CCN2. Results show that the suppression of endogenous CCN2 results in a significant decrease in AGGREGAN (Fig. 9C) and COLLAGEN II (Fig. 9D) and COLLAGEN I (Fig. 9E) mRNA expression. Moreover, the level of sulfated glycosaminoglycans is significantly declined in CCN2-suppressed cells (Fig. 9F).

**CCN2 Promotes Extracellular Matrix Production by Nucleus Pulposus Cells**—To support these in vitro silencing studies, we measured expression levels of proteoglycans in general and aggrecan in particular in discs of Ccn2 null mice. Fig. 9G shows that Ccn2 is expressed in the nucleus pulposus of the developing intervertebral disc. At E16.5, the nucleus pulposus is present in both WT and Ccn2 null littersmates, and there are no obvious differences. However, differences were apparent in E18.5 by safranin-o (Fig. 9H) and FAST staining (Fig. 9I). FAST staining is a multiple dye staining procedure that includes fast green, Alcian blue, safranin-o, and tartrazine, and thus detects collagens and proteoglycans. As shown in Fig. 9, H and I, there
is a relative paucity of safranin-O-stained proteoglycan in the nucleus pulposus of the mutant. Finally, we examined aggrecan levels by immunofluorescence (Fig. 9J). Consistent with the FAST staining analysis, lower levels of aggrecan are seen in the nucleus pulposis in Ccn2−/− mutants. Other details of the phenotypic analysis will be reported elsewhere, but the above results support the hypothesis that CCN2 is a regulator of aggrecan expression in the nucleus pulposus.

**DISCUSSION**

The experiments described in this investigation show that hypoxia regulates CCN2 expression through HIF-1α in nucleus
pulposus cells. We demonstrate that although hypoxia decreases CCN2 expression and promoter activity in a HIF-1α-dependent manner, direct binding of HIF-1 to HREs in the proximal CCN2 promoter is not required. We also observed that CCN2 regulates HIF-1α expression and activity, which may play a role in tissue homeostasis in both normal and degenerate discs.

Initially, we focused on the regulation of CCN2 by hypoxia.
of disc biology that regulates the expression of important cell survival and matrix genes in this tissue (7–10). Results of this study show that hypoxia decreased CCN2 transcription and protein levels in nucleus pulposus cells. Interestingly, in HCS-2/8 chondrosarcoma cells that are used to model chondrocyte behavior, hypoxia stabilizes CCN2 expression (37). Similarly, in several other cell types hypoxia was also shown to increase CCN2 expression (12, 27, 38); which in turn mediated the downstream effects of pathological hypoxia. Evidence to support the notion that CCN2 expression must be tightly regulated in tissues is apparent from transgenic mice that overexpress CCN2. Mice with two copies of Col1a2-Ccn2, which drives expression in fibroblasts, developed accelerated systemic multorgan fibrosis compared with mice with only one copy of the transgene, which showed a much later onset of fibrosis and longer lifespan (39). Likewise, increased fibrosis was observed in mice with liver-specific CCN2 overexpression, but only upon tissue injury. This observation suggests that perhaps induced inflammatory mediators could interact with CCN2 to promote increased fibrosis or that the inflammatory microenvironment could change the response of cells to CCN2 (40). This is relevant because CCN2 levels are elevated during disc degeneration, a condition characterized by tissue inflammation (23). Thus, it is reasonable to assume that whereas CCN2 is expressed in the developing nucleus pulposus and plays a role in maintenance of normal levels of aggrecan in this hypoxic niche, tight control of CCN2 expression is necessary to prevent excessive accumulation and to regulate its biological function (18, 23, 32, 34).

We next examined the mechanism by which hypoxia suppresses CCN2 expression in nucleus pulposus cells. For this

FIGURE 7. Knockdown of CCN2 in nucleus pulposus cells increases HIF-1α. A–C, real time RT-PCR analysis of cells transduced with control (Ctr-LV) or shCCN2 (shCCN2-LV) expressing lentivirus shows that CCN2 expression is decreased (A). Correspondingly, whereas HIF-1α expression is increased, that of HIF-2α is decreased (B). Expression of HIF-1 target genes, ENOLASE 1 (C) and VEGF expression (D), is increased in CCN2-silenced cells. E, Western blot analysis of nucleus pulposus cells transduced with control shRNA (Ctr-LV) or shCCN2 lentivirus (shCCN2-LV). HIF-1α protein increases with knockdown of CCN2. F, densitometric analysis of three independent experiments shows that transduction of cells with shCCN2 significantly decreases CCN2 expression (open bars), whereas increasing HIF-1α (black bars). Values shown are mean ± S.E. from three independent experiments, *, p < 0.05.
purpose, we chose to examine 4.0-kb proximal promoters of mouse and human CCN2. Importantly, studies of transgenic mice in which expression of nuclear-localized lacZ is driven by the 4-kb CCN2 proximal promoter have shown that this region is sufficient to drive high expression in the nucleus pulposus (34). We found that HIF-1α overexpression decreased CCN2 promoter activity, whereas siHIF-1α relieved hypoxic suppression of promoter activity. Further support for the role of HIF-1α in controlling CCN2 expression was forthcoming from loss- and gain-of-function experiments, which clearly showed a reciprocal relationship between HIF-1α and CCN2 levels in nucleus pulposus cells. These results were in accordance with previous studies showing the involvement of HIF-1α in hypoxic regulation of CCN2 in other cell types (12, 22, 27, 30, 42). Noteworthily, deletion and mutation analysis showed that the binding of HIF-1α to HREs contained within the studied promoter was not necessary for hypoxic repression of the activity.

The observation that CCN2 expression was less responsive to TGF-β treatment in hypoxia raised the possibility that hypoxia and HIF-1α may modulate canonical Smad signaling that is critical in maintenance of CCN2 expression in nucleus pulposus cells (23). Surprisingly, suppressive effects of hypoxia/HIF-1α did not involve interfering with the binding of Smad3 to the CCN2 promoter. This clearly suggests that in nucleus pulposus cells, regulation of CCN2 by HIF-1α is complex and may occur indirectly through modulation of binding of other regulatory factor(s) beside Smad3. This mode of regulation is similar to what we have previously observed in the context of HIF-1α.
regulation of Hsp70 and GlcAT-I promoters in nucleus pulposus cells (6, 11). Related to this discussion, one possibility is that hypoxia may exert its effects on CCN2 through the modulation of Fli1 or Ets-1, members of the Ets family of transcription factors. These factors function as molecular switches regulating a subset of target genes in response to physiological stimuli including hypoxia (43–45). Nakerakanti et al. (46) showed that Fli1 and Ets1 had differential effects on CCN2 expression in fibroblasts through differential occupancy of the Ets binding site, located at −114 bp in the proximal CCN2 promoter. Occupancy of this site by Fli1 had a suppressive effect on CCN2 gene expression, whereas occupancy by Ets-1 had a positive effect (46). It will be of interest to examine if, in nucleus pulposus cells, hypoxia controls the levels and binding ability of these factors to the CCN2 promoter in a HIF-1α-dependent fashion. This possibility is currently being examined.

We then investigated whether HIF-1α expression and activity is in turn controlled by CCN2. We observed an increase in HIF-1α and target gene expression with CCN2 knockdown. Correspondingly, decreased HRE reporter activity and
decreased HIF-1α target gene expression following treatment of cells with rCCN2 suggested that CCN2 may be involved in the maintenance of basal HIF-1α levels. Although these results are in contradiction to studies that reported a CCN2-mediated increase in HIF-1α levels in stromal fibroblasts and chondrosarcoma cells (24, 47), they are in agreement with a previous report of human lung adenocarcinoma (31). These investigators showed that lung adenocarcinomas with high levels of CCN2 exhibited lower HIF-1α levels and that in cultured cells, CCN2 decreased HIF-1α levels by enhancing its degradation through acetylation of Lys-532 and subsequent association with pVHL. Noteworthy, in nucleus pulposus cells, unlike previous studies, CCN2 treatment decreased the activity of HIF-1α-TAD reporters, suggesting that in addition to maintenance of basal levels it may affect the activity of the HIF-1α transcriptional complex. Furthermore, our study shows that in contrast to HIF-1α, CCN2 is a positive regulator of HIF-2α expression. This is relevant, as we have previously reported that in nucleus pulposus, HIF-2α controls the expression of ciedt2, a p300 interacting protein (29). By competing with HIF-α for p300 binding, ciedt2 suppresses transcriptional activity of HIF (29). Thus, it is possible that through induction of the HIF-2α-ciedt2 circuit, CCN2 may decrease HIF-1α activity and target gene expression. The details of the mechanism by which CCN2 controls HIF-1α levels/activity in the nucleus pulposus is not yet known and is a subject of future investigation.

Last, our study provided some insight into the role of endogenous CCN2 in nucleus pulposus cells. Both in vitro loss-of-function studies using postnatal nucleus pulposus cells and analysis of Ccn2 null mouse embryos showed a decrease in proteoglycan levels and a specific decrease in aggrecan accumulation, although the effect on proteoglycan matrix levels in the embryonic discs seemed modest. However, as matrix accumulation and turnover in a healthy disc is a slow process (41), it is possible that the cumulative effect of a small but continuous decrease in matrix production over time will have a significant impact on the structure and function of postnatal discs. Because Ccn2 global null is perinatally lethal, a nucleus pulposus-specific deletion of Ccn2 will be required to further investigate this possibility in postnatal tissue. Taken together, our results confirm that basal CCN2 levels in nucleus pulposus cells play a role in maintenance of proteoglycan-rich extracellular matrix and tissue homeostasis. However, as both CCN2 and HIF-1α have anabolic function in nucleus pulposus cells (10, 23, 32), it is plausible that their effect on matrix production is likely to be independent of each other. Importantly, this negative feedback loop may serve to tightly control both CCN2 and HIF-1α levels in the healthy disc. In summary, we show for the first time that in the nucleus pulposus, hypoxia regulates CCN2 in a HIF-1α-dependent manner, whereas CCN2 controls HIF-1α levels and activity. Further studies are needed to determine how HIF-1α regulation of CCN2 and vice versa could impact the progression of degenerative disc disease.

REFERENCES

1. Bartels, E. M., Fairbank, J. C., Winlove, C. P., and Urban, J. P. (1998) Oxygen and lactate concentrations measured in vivo in the intervertebral discs of patients with scoliosis and back pain. Spine (Phila Pa 1976) 23, 1–7
2. Hassel, O. (1969) The human intervertebral disc. A micro-angio-graphical study on its vascular supply at various ages. Acta Orthop. Scand. 40, 765–772
3. Rudert, M., and Tillmann, B. (1993) Lymph and blood supply of the human intervertebral disc. Cadaver study of correlations to discitis. Acta Orthop. Scand. 64, 37–40
4. Rajpurohit, R., Risbud, M. V., Ducheyne, P., Vre树林ie, E. J., and Shapiro, I. M. (2002) Phenotypic characteristics of the nucleus pulposus. Expression of hypoxia inducing factor-1, glucose transporter-1 and MMP-2. Cell Tissue Res. 308, 401–407
5. Fujita, N., Chiba, K., Shapiro, I. M., and Risbud, M. V. (2012) HIF-1α and HIF-2α degradation is differentially regulated in nucleus pulposus cells of the intervertebral disc. J. Bone Miner. Res. 27, 401–412
6. Gogate, S. S., Fujita, N., Skubutyte, R., Shapiro, I. M., and Risbud, M. V. (2012) Tonicity enhancer binding protein (TonEBP) and hypoxia-inducible factor (HIF) coordinate heat shock protein 70 (Hsp70) expression in hypoxic nucleus pulposus cells. Role of Hsp70 in HIF-1α degradation. J. Bone Miner. Res. 27, 1106–1117
7. Risbud, M. V., Guttapalli, A., Stokes, D. G., Hawkins, D., Danielson, K. G., Schaer, T. P., Albert, T. J., and Shapiro, I. M. (2006) Nucleus pulposus cells express HIF-1α under normoxic culture conditions. A metabolic adaptation to the intervertebral disc microenvironment. J. Cell. Biochem. 98, 152–159
8. Zeng, Y., Danielson, K. G., Albert, T. J., Shapiro, I. M., and Risbud, M. V. (2007) HIF-1α is a regulator of Galectin-3 expression in the intervertebral disc. J. Bone Miner. Res. 22, 1851–1861
9. Skubutyte, R., Markova, D., Freeman, T. A., Anderson, D. G., Dion, A. S., Williams, C. J., Shapiro, I. M., and Risbud, M. V. (2010) Hypoxia-inducible factor regulation of ANK expression in nucleus pulposus cells. Possible implications in controlling dystrophic mineralization in the intervertebral disc. Arthritis Rheum. 62, 2707–2715
10. Agrawal, A., Guttapalli, A., Narayan, S., Albert, T. J., Shapiro, I. M., and Risbud, M. V. (2007) Normoxic stabilization of HIF-1α drives glycolytic metabolism and regulates aggrecan gene expression in nucleus pulposus cells of the rat intervertebral disc. Am. J. Physiol. Cell Physiol. 293, C621–631
11. Gogate, S. S., Nasser, R., Shapiro, I. M., and Risbud, M. V. (2011) Hypoxic regulation of β-1,3-glucuronotransferase 1 expression in nucleus pulposus cells of the rat intervertebral disc. Role of hypoxia-inducible factor proteins. Arthritis Rheum. 63, 1950–1960
12. Shimo, T., Kubota, S., Kondo, S., Nakanishi, T., Sasaki, A., Mese, H., Matsumura, T., and Takigawa, M. (2001) Connective tissue growth factor binds to aggrecan. FEBS Lett. 508, 300–304
13. Ivan, S., Yoon, B. S., Popoff, S. N., Safadi, F. F., Libuda, D. E., Stephen-son, R. C., Daluiski, A., and Lyons, K. M. (2003) Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130, 2779–2791
14. Braig, S., Wallner, S., Junglas, B., Fuchshofer, R., and Bosserhoff, A. (2011) CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br. J. Cancer. 105, 231–238
15. Hall-Glenn, F., De Young, R. A., Huang, B. L., van Handel, B., Hofmann, J. L., Chen, T. P., Choi, A., Ong, J. R., Benya, P. D., Mikkola, H., Iruela-Arispe, M. L., and Lyons, K. M. (2012) CCN2/connexin 43 regulates connective tissue growth factor expression in the intervertebral disc. PLoS One 7, e30562–e30562
16. Hoshijima, M., Hattori, T., Inoue, M., Araki, D., Hanagata, H., Miyashita, A., and Takigawa, M. (2006) CT domain of CCN2/CTGF directly interacts with fibronectin and enhances cell adhesion of chondrocytes through integrin α5β1. FEBS Lett. 580, 1376–1382
17. Inoki, I., Shiomi, T., Hashimoto, G., Enomoto, H., Nakanishi, T., Makino, K., Ikeda, E., Takata, S., Kobayashi, K., and Okada, Y. (2002) Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16, 219–221
18. Aoyama, E., Hattori, T., Hoshijima, M., Araki, D., Nishida, T., Kubota, S., and Takigawa, M. (2009) N-terminal domains of CCN family 2/connexin 43 is regulated in the intervertebral disc. J. Bone Miner. Res. 27, 1106–1117
19. Gao, R., and Bristock, D. R. (2004) Connective tissue growth factor
Cross-talk between HIF-1α and CCN2 in the Nucleus Pulposus

(CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin α1β3 and heparan sulfate proteoglycan. J. Biol. Chem. 279, 8848–8855

20. Nishida, T., Kawaki, H., Baxter, R. M., Deyoung, R. A., Takigawa, M., and Lyons, K. M. (2007) CCN2 (connective tissue growth factor) is essential for extracellular matrix production and integrin signaling in chondrocytes. J. Cell. Commun. Signal. 1, 45–58

21. Abreu, J. G., Kepurua, N. I., Reversade, B., and De Robertis, E. M. (2002) Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nat. Cell. Biol. 4, 599–604

22. Higgins, D. F., Biju, M. P., Akai, Y., Wutz, A., Johnson, R. S., and Haase, V. H. (2004) Hypoxic induction of Ctgf is directly mediated by Hif-1. Am. J. Physiol. Renal Physiol. 287, F1223–1232

23. Tran, C. M., Markova, D., Smith, H. E., Susarla, B., Ponnappan, R. K., Anderson, D. G., Symes, A., Shapiro, I. M., and Risbud, M. V. (2010) Regulation of CCN2/CTGF expression in the nucleus pulposus of the intervertebral disc. Role of Smad and AP1 signaling. Arthritis Rheum. 62, 1983–1992

24. Nishida, T., Kondo, S., Maeda, A., Kubota, S., Lyons, K. M., and Takigawa, M. (2009) CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1α expression in a chondrocytic cell line, HCS-2/8, under hypoxic condition. Bone 44, 24–31

25. Ponticos, M., Holmes, A. M., Shi-wen, X., Leoni, P., Khan, K., Rajkumar, V. S., Hoyles, R. K., Bou-Gharios, G., Black, C. M., Denton, C. P., Abraham, D. J., Leask, A., and Lindahl, G. E. (2009) Pivotal role of connective tissue growth factor in lung fibrosis. MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 60, 2142–2155

26. Lee, C. H., Shah, B., Moioli, E. K., and Mao, J. J. (2010) CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J. Clin. Invest. 120, 3340–3349

27. Hong, K. H., Yoo, S. A., Kang, S. S., Choi, J. I., Kim, W. U., and Cho, C. S. (2006) Hypoxia induces expression of connective tissue growth factor in sclerodermia skin fibroblasts. Clin. Exp. Immunol. 146, 362–370

28. Bennewith, K. L., Huang, X., Ham, C. M., Graves, E. E., Erler, J. T., Kambham, N., Feazell, J., Yang, G. P., Koong, A., and Giaccia, A. J. (2009) The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 69, 775–784

29. Agrawal, A., Gaigghate, S., Smith, H., Anderson, D. G., Albert, T. J., Shapiro, J. M., and Risbud, M. V. (2008) Cited2 modulates hypoxia-inducible factor-dependent expression of vascular endothelial growth factor in nucleus pulposus cells of the rat intervertebral disc. Arthritis Rheum. 58, 3798–3808

30. Kroening, S., Neubauer, E., Wullich, B., Aten, J., and Goppel-Streube, M. (2010) Characterization of connective tissue growth factor expression in primary cultures of human tubular epithelial cells. Modulation by hypoxia. Am. J. Physiol. Renal Physiol. 298, F796–806

31. Chang, C. C, Lin, M. T., Lin, B. R., Jeng, Y. M., Chen, S. T., Chu, C. Y., Chen, R. J., Chang, K. J., Yang, P. C., and Kuo, M. L. (2006) Effect of connective tissue growth factor on hypoxia-inducible factor 1α degradation and tumor angiogenesis. J. Natl. Cancer Inst. 98, 984–995

32. Erwin, W. M., Ashman, K., O’Donnell, P., and Inman, R. D. (2006) Nucleus pulposus notochord cells secrete connective tissue growth factor and up-regulate proteoglycan expression by intervertebral disc chondrocytes. Arthritis Rheum. 54, 3859–3867

33. Chiou, M. J., Chao, T. T., Wu, J. L., Kuo, C. M., and Chen, J. Y. (2006) The physiological role of CTGF/CCN2 in zebrafish notochord development and biological analysis of the proximal promoter region. Biochem. Biophys. Res. Commun. 349, 750–758

34. Huang, B. L., Brugger, S. M., and Lyons, K. M. (2010) Stage-specific control of connective tissue growth factor (CTGF/CCN2) expression in chondrocytes by Sox9 and β-catenin. J. Biol. Chem. 285, 27702–27712

35. Leung, V. Y., Chan, W. C., Hung, S. C., Cheung, K. M., and Chan, D. (2009) Matrix remodeling during intervertebral disc growth and degeneration detected by multichromatic FAST staining. J. Histochem. Cytochem. 57, 249–256

36. Sandelin, A., Alkema, W., Engström, P., Wasserman, W. W., and Lenhard, B. (2004) JASPAR. An open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 32, D91–4

37. Kondo, S., Kubota, S., Mukudai, Y., Nishida, T., Yoshihama, Y., Shirata, T., Shintani, S., and Takigawa, M. (2011) Binding of glyceraldehyde-3-phosphate dehydrogenase to the cis-acting element of structure-anchored repression in ccn2 mRNA. Biochem. Biophys. Res. Commun. 405, 382–387

38. Gupta, S., Clarkson, M. R., Duggan, J., and Brady, H. R. (2000) Connective tissue growth factor. Potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int. 58, 1389–1399

39. Sonnylal, S., Shi-Wen, X., Leoni, P., Naff, K., Van Pelt, C. S., Nakamura, H., Leask, A., Abraham, D., Bou-Gharios, G., and de Crombrugghe, B. (2010) Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 62, 1523–1532

40. Tong, Z., Chen, R., Alt, D. S., Kemper, S., Perbal, B., and Bristock, D. R. (2009) Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes. Hepatology 50, 939–947

41. Sivan, S. S., Tisreron, E., Wachtel, E., Roughley, P. J., Sakke, N., van der Ham, F., DeGroot, J., Roberts, S., and Maroudas, A. (2006) Aggrecan turnover in human intervertebral disc as determined by the racemization of aspartic acid. J. Biol. Chem. 281, 13009–13014

42. Rimon, E., Chen, B., Shanks, A. L., Nelson, D. M., and Sadowsky, Y. (2008) Hypoxia in human trophoblasts stimulates the expression and secretion of connective tissue growth factor. Endocrinology 149, 2952–2958

43. Oikawa, M., Abe, M., Kurosawa, H., Hida, W., Shirato, K., and Sato, Y. (2001) Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem. Biophys. Res. Commun. 289, 39–43

44. Aryee, D. N., Niedan, S., Kauer, M., Schwentner, R., Benanani-Baiti, I. M., Ban, J., Muehlbacher, K., Kreppel, M., Walker, R. L., Meltzer, P., Poremba, C., Koller, R., and Kovar, H. (2010) Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing’s sarcoma cells in vitro. Cancer Res. 70, 4015–4023

45. Klappacher, G. W., Lunyk, V. V., Sykes, D. B., Sawka-Verhelle, D., Sage, I., Brard, G., Ngo, S. D., Gangadharan, D., Jacks, T., Kamps, M. P., Rose, D. W., Rosenfeld, M. G., and Glass, C. K. (2002) An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell 109, 169–180

46. Nakaraktani, S., Kapanadze, B., Yamasaki, M., Markiewicz, M., and Trojanowska, M. (2006) FlI1 and EtsI have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J. Biol. Chem. 281, 25259–25269

47. Capparelli, C., Whitaker-Menezes, D., Guido, C., Balliet, R., Pestell, T. G., Howell, A., Sneddon, S., Pestell, R. G., Martinez-Outschoorn, U., Lisanti, M. P., and Sotgia, F. (2012) CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 11, 2272–2284